| RESEARCH |
describe how R&D had been segmented into seven "entrepreneurial" research teams focused on specific therapeutic areas, thus establishing an agile "small-company culture" within the big corporation. The heads of the teams, called centers of excellence for drug discovery (CEDDs), each delivered a progress report. The bottom line: GSK now has 147 products in clinical trials, including 82 new chemical entities--a 46% increase in NCEs in two years. Also in development are 20 vaccines and 45 drugs on which the company is developing variants for new indications. GSK has 12 candidates in Phase III clinical trials, a 75% jump in two years. Garnier promised a record number of Investigational New Drug (IND) filings between 2004 and 2008, including a healthy number of drugs with "pioneering" mechanisms culled from genomics and biotechnology to address underserved therapeutic categories. |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |